The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.

While many of our models are solely available at QPS Neuropharmacology, all of them are well-characterized in house and published in peer reviewed high impact journals. Besides in vivo research we also offer biochemical and histological analyses. To support our clients in the best possible way, we use or adapt existing models, or establish new models specific to your research focus.

The animal facility of QPS Neuropharmacology is AAALAC accredited. This quality seal combined with over 20 years of experience and a vast amount of historic data are a clear asset for our clients, who range from international biotech and pharma companies to academia and other non- profit organizations. We assist with designing a developmental plan for your small molecules or biologics and together with our DMPK and Toxicology colleagues we help you develop custom-built research solutions.